Quarterly report pursuant to Section 13 or 15(d)

Statements of Cash Flows (Unaudited)

v3.7.0.1
Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Cash Flows from Operating Activities:    
Net loss $ (3,754) $ (1,071)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 8 1
Stock-based compensation 219 162
Deferred CEO compensation 63 0
Change in fair value of warrant liability 2,283 0
Gain in settlement of liability (149) 0
Gain from expiration of warrants (1,238) 0
Changes in operating assets and liabilities:    
Prepaid expenses (595) (315)
Accounts payable and accrued expenses (160) (422)
Net Cash Used in Operating Activities (3,323) (1,645)
Cash Flows from Investing Activities:    
Purchase of fixed assets (4) 0
Net Cash Used in Investing Activities (4) 0
Cash Flows from Financing Activities:    
Proceeds from notes payable 0 165
Payments on note payable 0 (470)
Proceeds from exercise of warrants 3,132  
Proceeds from sale of common stock units, net of cash stock issuance costs 4,460 9,167
Net Cash Provided by Financing Activities 7,592 8,862
Net change in cash and cash equivalents 4,265 7,217
Cash and cash equivalents, at beginning of period 5,007 28
Cash and cash equivalents, at end of period 9,272 7,245
Supplemental disclosures of cash flow information:    
Cash paid for interest 0 48
Cash paid for income taxes 0 0
Supplemental disclosure of non-cash investing and financing activities:    
Common stock issued for conversion of debt 302 201
Common stock issued for services provided 89 0
Assumption of accounts payable related to acquisition of Moleculin, LLC 0 100
Common stock issued to acquire Moleculin, LLC 0 9,774
Warrants exercised - not yet paid $ 34 $ 0